Skip to main content
SpringerLink
Log in

Comparing cost effectiveness of oral DDAs for chronic hepatitis C in China

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Chen P, et al. Cost-Effectiveness Analysis of Oral Direct-Acting Antivirals for Chinese Patients with Chronic Hepatitis C. Applied Health Economics and Health Policy : 19 Nov 2020. Available from: URL: https://doi.org/10.1007/s40258-020-00623-3

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Comparing cost effectiveness of oral DDAs for chronic hepatitis C in China. PharmacoEcon Outcomes News 867, 6 (2020). https://doi.org/10.1007/s40274-020-7303-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-020-7303-6

Search

Navigation